What to expect from Golden Helix in 2020!

· Andreas Scherer · About Golden Helix

Happy New Year! Certainly, I hope you had a relaxing time over the holidays with family and friends as well as a great start into the new year. 2019 was a real landmark year for Golden Helix. Please let me mention a few highlights:

  1. We launched VSClinical AMP in June 2019: This product is supporting the clinical variant interpretation based on ACMG & AMP guidelines. The product was an instant success.
  2. We received another $1.2M research grant from the NIH. This allows us to build out the most advanced clinical workflow solution interpreting next-gen sequencing data. A particular focus on this work is to deeply integrate CNV analytics capabilities in this context.
  3. Last but not least, Inc 5000 selected us among the fastest-growing private companies in the United States.

Now, for 2020 we will plan to continue to build on this success. Here are some key elements of our strategy for this year.

  1. We will continue to strengthen our capabilities in regards to interpreting cancer-related diseases. There will be additional features in our VSClinical AMP product in the first half of this year.
  2. Our CNV analytics capabilities will continue to strengthen. We are focusing on the deep integration of our CNV capabilities into our clinical interpretation and reporting workflows. We also are at the forefront of implementing the most recent guidelines in this context.
  3. We have advanced capabilities to deploy our clinical stack in highly secure environments. We were able to develop our stack in a way that doesn’t require any internet connectivity to function fully operating behind a firewall. This is key for highly regulated applications that have to adhere to the highest security standards.

Ultimately, it is our goal to create the best possible user experience for our customers in any type of implementation scenario, such as on-premises, cloud or in a mixed environment. Our team is highly motivated to ensure your success. Thanks for your loyalty and the tremendous support we have received.

I wish you personally a very prosperous and successful year 2020!

Leave a comment

Andreas Scherer

About Andreas Scherer

Dr. Andreas Scherer is CEO of Golden Helix. The company has been delivering industry leading bioinformatics solutions for the advancement of life science research and translational medicine for over a decade. Its innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from next-generation sequencing. With its solutions, hundreds of the world’s hospitals and testing labs are able to harness the full potential of genomics to identify the cause of disease, develop genomic diagnostics, and advance the quest for personalized medicine. Golden Helix products and services have been cited in thousands of peer-reviewed publications. Golden Helix is also on the Inc 5000 list of the fastest-growing private companies in the US. He is also Managing Partner of Salto Partners, Inc, a management consulting firm headquartered in Nevada.  He has extensive experience successfully managing growth as well as orchestrating complex turnaround situations. His company, Salto Partners, advises on business strategy, financing, sales, and operations. Clients are operating in the high-tech and life sciences space. Dr. Scherer holds a Ph.D. in computer science from the University of Hagen, Germany, and a Master of Computer Science from the University of Dortmund, Germany. He is author and co- author of over 20 international publications and has written books on project management, the Internet, and artificial intelligence. His latest book, “Be Fast Or Be Gone”, is a prizewinner in the 2012 Eric Hoffer Book Awards competition, and has been named a finalist in the 2012 Next Generation Indie Book Awards! 

View all posts by Andreas Scherer →